Abstract
Chemical reduction with trisodium citrate as the reducing agent resulted in the successful formation of palladium nanoparticles (Pd NPs), and all of the material's components were synthesised in double-distilled water. UV-vis spectroscopy, X-ray diffraction, with Transmission Electron Microscopy were all utilised to investigate the Pd nanoparticles. According to TEM investigations, the average size of the Pd nanoparticles formed was 13.5 - 45 nm. Serum adenosine deaminase (ADA) activity in atherosclerosis patients was tested to see if Pd NPs had any effect. Serum ADA activity was considerably higher in individuals with atherosclerotic disease, both in those treated with Pd nanoparticles and in those who were not (P<0.01). Pd nanoparticles significantly lowered blood levels of ADA activity in atherosclerotic disease patients compared to those who did not receive Pd nanoparticles.